Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digoxin-rifampin interaction.

H Gault, L Longerich, M Dawe

    Clinical Pharmacology and Therapeutics
    |June 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Rifampin significantly alters digoxin levels in dialysis patients. Starting rifampin increases required digoxin doses, while stopping it causes levels to drop, potentially leading to toxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Observed psychopathology in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia.

    Psychological medicine·2019
    Same author

    Examining predictors of help-seeking behaviours in patients with mood and anxiety symptoms.

    Psychiatry research·2018
    Same author

    Genetic testing for BRCA1 and BRCA2 in the Province of Ontario.

    Clinical genetics·2015
    Same author

    Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy.

    Lupus·2015
    Same author

    Development of SLE among "potential SLE" patients seen in consultation: long-term follow-up.

    International journal of clinical practice·2014
    Same author

    [Anthropological approach to current parental perceptions of children's seizures].

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Nephrology
    • Drug Interactions

    Background:

    • Digoxin is a crucial medication for managing heart failure and arrhythmias.
    • Patients with chronic kidney disease often require digoxin and may undergo dialysis.
    • Rifampin is an antibiotic commonly used to treat tuberculosis and other infections.

    Observation:

    • Two dialysis-dependent patients experienced a significant increase in required digoxin doses upon initiating rifampin therapy.
    • Following the discontinuation of rifampin, digoxin doses returned to pre-rifampin levels.

    Findings:

    • Rifampin significantly impacts digoxin pharmacokinetics in patients on dialysis.
    • Serum digoxin concentrations fluctuated dramatically, indicating a substantial drug interaction.

    Related Experiment Videos

  • This interaction necessitates careful monitoring of digoxin levels during rifampin therapy and upon its cessation.

    • Implications:

    • Clinicians must be aware of the potential for significant digoxin level changes when co-administering rifampin and digoxin in dialysis patients.
    • Therapeutic drug monitoring is essential to prevent subtherapeutic or toxic digoxin levels.
    • Dosage adjustments are critical to ensure patient safety and treatment efficacy.